SG3 Management’s CRISPR Therapeutics CRSP Stock Holding History

SG3 Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-27,000	Closed	-$3.02M	–	1079
2021 Q3	$3.02M	Buy	27,000 +15,000	+125%	+$1.88M	0.09%	218
2021 Q2	$1.94M	Sell	12,000 -27,500	-70%	-$3.34M	0.07%	321
2021 Q1	$4.81M	Buy	39,500 +29,500	+295%	+$4.45M	0.12%	186
2020 Q4	$1.53M	Buy	+10,000	New	+$1.18M	0.03%	457
2020 Q3	–	Sell	-70,000	Closed	-$5.14M	–	913
2020 Q2	$5.14M	Buy	+70,000	New	+$4.09M	0.36%	64

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SG3 Management's CRSP Position: Q4 2021 in Review

SG3 Management sold out of CRISPR Therapeutics (CRSP) in Q4 2021, closing a stake of 1,000 shares — an estimated $87.4K sold.

SG3 Management first reported a position in CRSP in Q1 2021 and held it in 2 quarters. The position peaked at $2.13M in Q1 2021. 446 funds tracked by Wall St. Rank hold CRSP as of Q4 2021.

SG3 Management reported no remaining CRISPR Therapeutics position as of Q4 2021 after selling out during the quarter.
SG3 Management sold 1,000 CRISPR Therapeutics shares in Q4 2021, an estimated $87.4K.
SG3 Management first reported a position in CRISPR Therapeutics in Q1 2021 and held it in 2 quarters.
SG3 Management's CRISPR Therapeutics position peaked at $2.13M in Q1 2021.
446 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2021.

Based on SG3 Management's 13F filing for Q4 2021, filed 15 Feb 2022.